Free Trial

Ultralife (NASDAQ:ULBI) Share Price Crosses Above 200 Day Moving Average - Time to Sell?

Ultralife logo with Computer and Technology background
Image from MarketBeat Media, LLC.

Key Points

  • Technical move: Ultralife's shares crossed above their 200-day moving average (200‑day SMA $6.27) Monday, trading as high as $6.63 and last at $6.55 (50‑day SMA $6.23).
  • Analyst sentiment remains negative: Weiss Ratings reissued a "sell (d+)" and the stock's average rating on MarketBeat is "Sell."
  • Weak fundamentals/earnings: The most recent quarter missed expectations—$0.12 EPS vs. $0.24 expected and $48.48M revenue vs. $57.00M consensus—with a negative net margin and a negative P/E.
  • Interested in Ultralife? Here are five stocks we like better.

Ultralife Corporation (NASDAQ:ULBI - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.27 and traded as high as $6.63. Ultralife shares last traded at $6.55, with a volume of 24,259 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a "sell (d+)" rating on shares of Ultralife in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Ultralife has an average rating of "Sell".

Read Our Latest Stock Report on Ultralife

Ultralife Stock Up 1.9%

The company has a quick ratio of 1.42, a current ratio of 2.99 and a debt-to-equity ratio of 0.34. The stock's 50-day simple moving average is $6.23 and its 200 day simple moving average is $6.27. The firm has a market cap of $109.06 million, a P/E ratio of -18.19 and a beta of 0.88.

Ultralife (NASDAQ:ULBI - Get Free Report) last posted its quarterly earnings data on Tuesday, March 10th. The technology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.12). Ultralife had a positive return on equity of 3.06% and a negative net margin of 3.09%.The business had revenue of $48.48 million during the quarter, compared to the consensus estimate of $57.00 million.

Hedge Funds Weigh In On Ultralife

Several institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd boosted its holdings in shares of Ultralife by 19.9% during the 4th quarter. XTX Topco Ltd now owns 15,456 shares of the technology company's stock worth $88,000 after buying an additional 2,569 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Ultralife by 30.7% in the 4th quarter. Bank of America Corp DE now owns 12,067 shares of the technology company's stock valued at $90,000 after acquiring an additional 2,836 shares in the last quarter. Pitti Group Wealth Management LLC lifted its position in shares of Ultralife by 20.0% during the 3rd quarter. Pitti Group Wealth Management LLC now owns 17,981 shares of the technology company's stock valued at $123,000 after acquiring an additional 3,000 shares during the period. Lazard Asset Management LLC lifted its position in shares of Ultralife by 1,650.0% during the 2nd quarter. Lazard Asset Management LLC now owns 5,565 shares of the technology company's stock valued at $49,000 after acquiring an additional 5,247 shares during the period. Finally, Empowered Funds LLC bought a new position in Ultralife during the fourth quarter worth $44,000. 30.68% of the stock is owned by institutional investors and hedge funds.

Ultralife Company Profile

(Get Free Report)

Ultralife Corporation NASDAQ: ULBI develops, manufactures and sells a broad range of energy and communications products for defense, medical, automotive and consumer electronics markets. The company operates through two primary segments: Power Systems and Communications Systems. In its Power Systems segment, Ultralife produces lithium-ion rechargeable cells and battery packs, primary lithium batteries, alkaline and rechargeable battery packs, chargers and battery accessories designed to meet demanding performance and safety requirements.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ultralife Right Now?

Before you consider Ultralife, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultralife wasn't on the list.

While Ultralife currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines